ICUI vs INFU
ICUI: A medical device manufacturer specializing in comprehensive infusion therapy systems and critical care technology. INFU: A national healthcare service provider facilitating clinic-to-home infusion therapy through durable medical equipment rental, sales, and comprehensive patient support services.
Side-by-side fundamentals
| Metric | ICUI | INFU | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $161.08 | $14.23 | |
| Market cap as of 2026-07-31 (share count; price 2026-10-20) | $4.0B | $283M | |
| P/E as of 2026-10-20 | 135.36 | 35.57 | INFU lower |
| Net margin FY2025, SEC XBRL | +0.0% | +4.6% | INFU higher |
| Gross margin FY2025, SEC XBRL | +36.8% | +56.0% | INFU higher |
| Operating margin FY2025, SEC XBRL | +1.9% | +8.3% | INFU higher |
| ROE FY2025, SEC XBRL | +0.0% | +11.6% | INFU higher |
| ROA FY2025, SEC XBRL | +0.0% | +6.6% | INFU higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | 0.57 | 0.35 | INFU lower |
| Revenue growth (YoY) FY2025, SEC XBRL | -6.3% | +6.4% | INFU higher |
| Revenue CAGR (3y) SEC XBRL | -0.7% | +9.3% | INFU higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.01 | 1.13 | |
| 1-year return as of 2026-10-20 close | +37.3% | +48.2% | INFU higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.